Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying ...

Celcuity received FDA approval for REVTORPYK for certain metastatic breast cancer patients and was included as a preferred option in updated treatment guidelines, though its share price has pulled back significantly even as long-term returns remain strong.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.